Skip to content

15 November 2021

Boreham’s Crucible: Breaking down ASX aspirant Artrya’s AI heart disease warning system

Tim-Boreham

In this Stockhead article, Tim Boreham dives into Artrya as a company and shares his thoughts in the current $100M market valuation. He also speaks on Artya's recent accomplishments as well as goals in the months and years to come. Read more here.